Lethal Effect Of Adenovirus-mediated CD-TK Fusion Gene On Human Bladder Tumor Cells In Vitro And The Inhibition Of The Tumor Growth In Vivo

Background The bladder transitional-cell tumor (TCC) is the highest incidence of urinary system. It is the fourth incidence of all the tumors in man, and the eighth in woman. There will add 50,000 new patients every year in America. When diagnosed, there are 75%-80% of the patients that have not infiltrate the muscles of the bladder (T₁N₀M₀), but others did. When treat the T₁N₀M₀ carcinomas, the transurethral resection of bladder tumor (TURBt) was the first choice. If treated with the TURBt only, 50%-70% of the patients will palindromia. And 10%-15% of them will turn to invasion TCC. And 30% of the invasion TCC patients will die in 2 years. To prevent the palindromia after TURBt, infuse drugs into bladder after TURBt is now the most effective way. The most frequent used drugs are mitomycin (MMC) and Bacillus Calmette-Guerin (BCG) et al. This method can decrease 20% rate of palindromia. But after infuse, there are still 30%-50% of the patients will palindromia. And it will not be changed that 10%-15% of them will become invasion TCC. So we need to find out a new method to treat TCC. Gene therapy is a promising new method. The most extensively used strategy is suicide gene therapy. The suicide genes are those that have the ability to convert a nontoxic prodrug into...